MolSoft LLC retweeted
Was amused to find our V-SYNTHES paper mentioned in THIS blog in the same paragraph with Google's Isomorphic labs and InSilico Medicine clinical trials. Singularity is near! 😎
singularityhub.com/2022/01/0…
MolSoft LLC retweeted
Scientific Applications under Big Sur, if you have info let me know and update the page. macinchem.org/blog/files/1fd… #BigSur
MolSoft LLC retweeted
Free Webinar - MolScreen: Combining Deep Learning with Docking. Thousands of preclinical activity assays for drug candidates in silico. Register here: register.gotowebinar.com/reg… includes a free 2 week software license
#compchem #drugdesign #cheminformatics #medchem
MolSoft LLC retweeted
MolSoft docking showed affinity of Umifenovir to coronavirus Nsp7_Nsp8 complex, Nsp14, Nsp15, E-channel, or Spike protein - sciencedirect.com/science/ar… However it may be spurious result. Given the activity of Umifenovir against Influenza, cell structures are more plausible targets.
MolSoft LLC retweeted
Bacterial #drugresistance is a massive clinical problem. #Qpex @MolSoft @USouthFlorida develop QPX7728, a broad spectrum B-lactamase inhibitor to be used in combination with B-lactam antibiotics to treat multidrug resistant infections. Genes by @ATUM_bio pubs.acs.org/doi/abs/10.1021…
MolSoft LLC retweeted
KRAS mini news dump: first glimpse at human data for Mirati's G12C inhibitor; encouraging mouse data on value of combining AMG510 & anti-PD1s; and a look at Boehringer's new clinical entrant, a SOS:KRAS inhibitor: cen.acs.org/pharmaceuticals/…
MolSoft LLC retweeted
Structures for arguably two most valuable compounds in oncology pipeline today $AMGN $MRTX
Both made possible only after structural insights and tool compounds from this 2013 seminar paper on drugging KRAS G12C. Kudos to @kevansf and Wellspring team!
nature.com/articles/nature12…
MolSoft LLC retweeted
Scientific Applications under Catalina goo.gl/fb/3wGqZx
MolSoft LLC retweeted
Harnessing Ion-Binding Sites for GPCR Pharmacology pharmrev.aspetjournals.org/c…
MolSoft LLC retweeted
A very dangerous signal from the demise of Achaogen - “The tragedy is not that investors have lost their money. Rather, it is the signal that there is no viable route to market for new antibiotics, however valuable they may be to society”. ft.com/content/4da1c6e4-603d…
MolSoft LLC retweeted
Check it out... Dr. Ruben Abagyan of @UCSDSkaggsSOP was on @KUSINews last night to talk about a new ketamine nasal spray that's intended to treat depression: kusi.com/new-fda-approved-dr…
MolSoft LLC retweeted
Please join us for MolSoft's 2018 ICM User Group Meeting. Registration and more information here: molsoft.com/training.html #compchem #bioinformatics #cheminformatics #rna #qsar #drugdiscovery
MolSoft LLC retweeted
MolSoft's ICM Ranks First in Independent Covalent Docking Tools Comparison pubs.acs.org/doi/10.1021/acs… #compchem #drugdesign #medchem #drugdiscovery
MolSoft LLC retweeted
MolSoft's ICM-pro Ranks First in Independent Covalent Docking Tools Comparisonhttps://pubs.acs.org/doi/10.1021/acs.jcim.8b00228 pubs.acs.org/doi/10.1021/acs…
MolSoft LLC retweeted
Check out "MolSoft ICM User Group Meeting 2018" eventbrite.com/e/molsoft-icm… @Eventbrite
MolSoft LLC retweeted
Totrov: Incorporating biasing based on template ligands. Atomic Property Fields (APF) encoding chemical properties. #D3R2018
MolSoft LLC retweeted
Totrov on pose & affinity prediction #D3R2018 – at San Diego, CA
MolSoft LLC retweeted
Next, Max Totrov (Molsoft), pose and affinity prediction by ICM in D3R GC3. #D3R2018
MolSoft LLC retweeted
You are cordially invited to join the live web-broadcast of the two-day D3R/SAMPL workshop starting tomorrow! Register here for the webinar: register.gotowebinar.com/reg…
View he workshop agenda here: drugdesigndata.org//about/d3…
#compchem





















